Previous Close | 4.6400 |
Open | 4.4729 |
Bid | 4.4400 x 1000 |
Ask | 4.5300 x 900 |
Day's Range | 4.4900 - 4.5600 |
52 Week Range | 3.5000 - 23.2500 |
Volume | |
Avg. Volume | 20,714 |
Market Cap | 155.562M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3180 |
Earnings Date | Aug 11, 2020 - Aug 17, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
InVivo Therapeutics Holdings Corp (NASDAQ: NVIV) has announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focusing on treating spinal cord injuries. The company anticipates the reverse stock split will become effective and start trading on a post-split basis on April 27. Every 25 shares of InVivo Therapeutics common stock will be combin
InVivo Therapeutics Holdings Corp. said Thursday it will carry out a 1-for-25 reverse stock split, which is intended to increase the per-share trading price of its stock and fulfill the Nasdaq Capital Market's $1 minimum bid price requirement.
CAMBRIDGE, Mass., April 14, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 26, 2022, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the company's existing trading symbol, "NVIV," at the market open on April 27, 2022. T